Valuation: Madrigal Pharmaceuticals, Inc.

Market Cap 11.55B 10.25B 9.59B 8.74B 16.45B 1,112B 16.68B 116B 44.91B 566B 43.35B 42.41B 1,818B P/E 2026 *
-79.5x
P/E 2027 * 92.1x
Enterprise Value 11.02B 9.79B 9.15B 8.34B 15.7B 1,061B 15.92B 111B 42.87B 540B 41.38B 40.48B 1,736B EV / Sales 2026 *
7.22x
EV / Sales 2027 * 4.98x
Free-Float
94.17%
Yield 2026 *
-
Yield 2027 * -
1 week-1.33%
Current month-0.02%
1 month-3.94%
3 months-1.83%
6 months-2.59%
Current year-10.32%
1 week 439.4
Extreme 439.4
458.8
1 month 439.4
Extreme 439.4
471.6
3 years 113.8
Extreme 113.8
519.6
5 years 48.4
Extreme 48.4
519.6
10 years 11.34
Extreme 11.34
519.6
Manager TitleAgeSince
Chief Executive Officer 59 07/09/2023
Director of Finance/CFO 62 10/03/2024
Chief Tech/Sci/R&D Officer 58 20/04/2025
Director TitleAgeSince
Director/Board Member 74 30/06/2016
Director/Board Member 68 10/08/2016
Director/Board Member 64 26/06/2019
Change 5-day change 1-year change 3-year change Capi.($)
-0.02%-1.38%+15.92%+202.42% 11.64B
+4.16%+3.04%+49.37%+94.17% 74.46B
-0.61%+0.81%+27.25%+82.72% 60.14B
-2.54%-1.65%+4.86%+31.72% 48.15B
-3.02%-5.20%+27.94%+32.51% 44.25B
+0.31%+3.02%+348.95%+643.82% 43.99B
-1.96%-0.33%+7.04%+99.46% 41.61B
+3.32%+3.49%+10.10%+51.23% 29.97B
-3.39%+2.17%+28.68%+21.82% 29.31B
-4.86%-10.66%-26.27%+330.06% 24.93B
Average -0.95%-0.08%+49.38%+158.99% 44.09B
Weighted average by Cap. -0.43%+0.11%+56.57%+147.32%

Financials

2026 *2027 *
Net sales 1.53B 1.36B 1.27B 1.16B 2.18B 147B 2.21B 15.35B 5.94B 74.9B 5.73B 5.61B 241B 2.13B 1.89B 1.77B 1.61B 3.03B 205B 3.07B 21.39B 8.28B 104B 7.99B 7.82B 335B
Net income -183M -163M -152M -139M -261M -17.62B -264M -1.84B -712M -8.97B -687M -672M -28.82B 179M 159M 149M 135M 255M 17.23B 258M 1.8B 696M 8.77B 672M 657M 28.18B
Net Debt -525M -466M -436M -397M -747M -50.5B -758M -5.27B -2.04B -25.72B -1.97B -1.93B -82.61B -943M -838M -783M -714M -1.34B -90.81B -1.36B -9.48B -3.67B -46.25B -3.54B -3.46B -149B
Logo Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Employees
-
Date Price Change
01/10/26 €444.10 -0.02%
30/09/26 €444.20 -0.54%
29/09/26 €446.60 -1.33%
28/09/26 €452.60 -0.07%
25/09/26 €452.90 +0.62%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
19
Last Close Price
499.71USD
Average target price
682.11USD
Spread / Average Target
+36.50%

Quarterly revenue - Rate of surprise